The Manufacturers Life Insurance Company Grows Stake in Tyra Biosciences, Inc. $TYRA

The Manufacturers Life Insurance Company lifted its position in Tyra Biosciences, Inc. (NASDAQ:TYRA) by 381.3% during the 1st quarter, HoldingsChannel reports. The firm owned 40,224 shares of the company’s stock after buying an additional 31,867 shares during the period. The Manufacturers Life Insurance Company’s holdings in Tyra Biosciences were worth $1,541,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Jennison Associates LLC purchased a new stake in shares of Tyra Biosciences in the 1st quarter valued at about $24,222,000. 5AM Venture Management LLC raised its stake in Tyra Biosciences by 9.6% in the fourth quarter. 5AM Venture Management LLC now owns 1,029,298 shares of the company’s stock valued at $27,060,000 after purchasing an additional 90,000 shares in the last quarter. Seven Fleet Capital Management LP purchased a new stake in Tyra Biosciences in the fourth quarter valued at approximately $2,092,000. Strs Ohio lifted its position in Tyra Biosciences by 2,485.7% during the first quarter. Strs Ohio now owns 18,100 shares of the company’s stock valued at $693,000 after purchasing an additional 17,400 shares during the last quarter. Finally, Fisher Asset Management LLC purchased a new position in Tyra Biosciences in the 4th quarter worth approximately $757,000. Hedge funds and other institutional investors own 84.14% of the company’s stock.

Wall Street Analyst Weigh In

TYRA has been the topic of several research reports. Bank of America raised their price objective on shares of Tyra Biosciences from $37.00 to $42.00 and gave the company a “buy” rating in a research report on Wednesday, June 10th. Wolfe Research started coverage on Tyra Biosciences in a research report on Tuesday, May 19th. They set a “peer perform” rating on the stock. HC Wainwright reaffirmed a “buy” rating and set a $45.00 price target on shares of Tyra Biosciences in a research note on Thursday, May 14th. Guggenheim started coverage on Tyra Biosciences in a report on Tuesday, April 14th. They issued a “buy” rating and a $54.00 price objective for the company. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Tyra Biosciences in a research report on Friday, July 17th. One investment analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $46.90.

Tyra Biosciences Price Performance

Shares of TYRA stock opened at $26.25 on Tuesday. The business has a 50-day moving average of $29.96 and a 200 day moving average of $32.66. Tyra Biosciences, Inc. has a 1-year low of $9.96 and a 1-year high of $40.65. The stock has a market capitalization of $1.57 billion, a PE ratio of -10.94 and a beta of 0.77.

Tyra Biosciences (NASDAQ:TYRA) last issued its earnings results on Tuesday, August 4th. The company reported ($0.69) EPS for the quarter, missing the consensus estimate of ($0.65) by ($0.04). Analysts anticipate that Tyra Biosciences, Inc. will post -2.72 EPS for the current year.

Tyra Biosciences Profile

Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.

The company’s pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.